[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100599140":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":19,"responsibleParty":26,"collaborators":19,"id":28,"slug":29,"hasResults":30,"nctId":31,"briefTitle":32,"officialTitle":33,"acronym":19,"eligibilityCriteria":34,"healthyVolunteers":30,"sex":35,"minAge":36,"maxAge":37,"enrollmentInfo":38,"targetDuration":19,"studyType":41,"phases":42,"briefSummary":44,"conditions":45,"keywords":48,"overallStatus":49,"whyStopped":19,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":19},{"fullName":5,"class":6},"Tianjin ConjuStar Biologics Co., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"TNBC, HR+HER2- BC, and other tumors","EXPERIMENTAL","Receive 7.5 mg\u002Fm² of SC-101 intravenously once weekly (QW).",[13],"Drug: SC-101",[15],{"type":16,"name":17,"description":11,"armGroupLabels":18,"otherNames":19},"DRUG","SC-101",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Jing Wu Wu","CONTACT","021-33670866","wujing@conjustar.com",{"type":27,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100599140","phase-2-sc-101-in-subjects-with-advanced-nectin4-amplified-cancers-100599140",false,"NCT07080619","SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers","A Phase IIa Clinical Study to Assess the Efficacy and Safety of SC-101 in Patients With Advanced Malignant Tumors Positive for NECTIN4 Gene Amplification","Inclusion Criteria:\n\nAge between 18 and 75 years (inclusive), regardless of gender.\n\nECOG performance status of 0-1.\n\nExpected survival of more than 3 months, as assessed by the investigator.\n\nFertile participants must agree to use contraception.\n\nAble to understand the trial requirements and willing and able to comply with the trial and follow-up procedures.\n\nAdequate bone marrow and organ function.\n\nNECTIN-4 gene amplification positive.\n\nExclusion Criteria:\n\nUnstable central nervous system tumors.\n\nAdverse reactions from previous anticancer treatments have not recovered to a CTCAE 5.0 grade ≤1.\n\nA history of severe cardiovascular or cerebrovascular disease.","ALL","18 Years","75 Years",{"count":39,"type":40},120,"ESTIMATED","INTERVENTIONAL",[43],"PHASE2","This study is an open-label, multicenter Phase IIa trial to evaluate the efficacy and safety of SC-101 monotherapy in patients with locally advanced or metastatic malignant tumors who are positive for NECTIN4 gene amplification.",[46,47],"TNBC - Triple-Negative Breast Cancer","HR+ Breast Cancer",[17],"NOT_YET_RECRUITING","2025-09-04",{"date":52,"type":53},"2025-09-11","ACTUAL",{"date":55,"type":40},"2025-09-20",{"date":57,"type":40},"2027-12-30",{"name":5,"class":6}]